170 related articles for article (PubMed ID: 28508842)
21. Bisphenol S promotes the cell cycle progression and cell proliferation through ERα-cyclin D-CDK4/6-pRb pathway in MCF-7 breast cancer cells.
Lin Z; Zhang X; Zhao F; Ru S
Toxicol Appl Pharmacol; 2019 Mar; 366():75-82. PubMed ID: 30684532
[TBL] [Abstract][Full Text] [Related]
22. The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.
Tanaka S; Suzuki K; Sakaguchi M
Breast Cancer; 2017 Sep; 24(5):658-666. PubMed ID: 28070831
[TBL] [Abstract][Full Text] [Related]
23. The adenosine A3 receptor agonist Cl-IB-MECA induces cell death through Ca²⁺/ROS-dependent down regulation of ERK and Akt in A172 human glioma cells.
Kim TH; Kim YK; Woo JS
Neurochem Res; 2012 Dec; 37(12):2667-77. PubMed ID: 22878643
[TBL] [Abstract][Full Text] [Related]
24. Fascaplysin inhibit ovarian cancer cell proliferation and metastasis through inhibiting CDK4.
Chen S; Guan X; Wang LL; Li B; Sang XB; Liu Y; Zhao Y
Gene; 2017 Nov; 635():3-8. PubMed ID: 28888575
[TBL] [Abstract][Full Text] [Related]
25. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells.
Fishman P; Madi L; Bar-Yehuda S; Barer F; Del Valle L; Khalili K
Oncogene; 2002 Jun; 21(25):4060-4. PubMed ID: 12037688
[TBL] [Abstract][Full Text] [Related]
26. Suppression of inflammation response by a novel A₃ adenosine receptor agonist thio-Cl-IB-MECA through inhibition of Akt and NF-κB signaling.
Lee HS; Chung HJ; Lee HW; Jeong LS; Lee SK
Immunobiology; 2011 Sep; 216(9):997-1003. PubMed ID: 21514967
[TBL] [Abstract][Full Text] [Related]
27. Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist.
Fishman P; Bar-Yehuda S; Ardon E; Rath-Wolfson L; Barrer F; Ochaion A; Madi L
Anticancer Res; 2003; 23(3A):2077-83. PubMed ID: 12894581
[TBL] [Abstract][Full Text] [Related]
28. Effect of the WWOX gene on the regulation of the cell cycle and apoptosis in human ovarian cancer stem cells.
Yan H; Tong J; Lin X; Han Q; Huang H
Mol Med Rep; 2015 Aug; 12(2):1783-8. PubMed ID: 25891642
[TBL] [Abstract][Full Text] [Related]
29. IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis.
Rath-Wolfson L; Bar-Yehuda S; Madi L; Ochaion A; Cohen S; Zabutti A; Fishman P
Clin Exp Rheumatol; 2006; 24(4):400-6. PubMed ID: 16956430
[TBL] [Abstract][Full Text] [Related]
30. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells.
Masamha CP; Benbrook DM
Cancer Res; 2009 Aug; 69(16):6565-72. PubMed ID: 19638577
[TBL] [Abstract][Full Text] [Related]
31. A3 adenosine receptor agonist potentiates natural killer cell activity.
Harish A; Hohana G; Fishman P; Arnon O; Bar-Yehuda S
Int J Oncol; 2003 Oct; 23(4):1245-9. PubMed ID: 12964011
[TBL] [Abstract][Full Text] [Related]
32. An adenosine A3 receptor agonist inhibits DSS-induced colitis in mice through modulation of the NF-κB signaling pathway.
Ren T; Tian T; Feng X; Ye S; Wang H; Wu W; Qiu Y; Yu C; He Y; Zeng J; Cen J; Zhou Y
Sci Rep; 2015 Mar; 5():9047. PubMed ID: 25762375
[TBL] [Abstract][Full Text] [Related]
33. Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells.
Morello S; Sorrentino R; Porta A; Forte G; Popolo A; Petrella A; Pinto A
J Cell Physiol; 2009 Nov; 221(2):378-86. PubMed ID: 19562684
[TBL] [Abstract][Full Text] [Related]
34. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection.
Fishman P; Bar-Yehuda S; Barer F; Madi L; Multani AS; Pathak S
Exp Cell Res; 2001 Oct; 269(2):230-6. PubMed ID: 11570815
[TBL] [Abstract][Full Text] [Related]
35. The effects of the adenosine A3 receptor agonist IB-MECA on sodium taurocholate-induced experimental acute pancreatitis.
Prozorow-Krol B; Korolczuk A; Czechowska G; Slomka M; Madro A; Celinski K
Arch Pharm Res; 2013 Sep; 36(9):1126-32. PubMed ID: 23625750
[TBL] [Abstract][Full Text] [Related]
36. A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition.
Madi L; Bar-Yehuda S; Barer F; Ardon E; Ochaion A; Fishman P
J Biol Chem; 2003 Oct; 278(43):42121-30. PubMed ID: 12865431
[TBL] [Abstract][Full Text] [Related]
37. Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway.
Wang G; Cao R; Wang Y; Qian G; Dan HC; Jiang W; Ju L; Wu M; Xiao Y; Wang X
Sci Rep; 2016 Oct; 6():35783. PubMed ID: 27779188
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of cyclin-dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1.
Bhowmik T; Gomes A
Chem Biol Interact; 2017 Apr; 268():119-128. PubMed ID: 28322778
[TBL] [Abstract][Full Text] [Related]
39. A3 adenosine receptor antagonist, truncated Thio-Cl-IB-MECA, induces apoptosis in T24 human bladder cancer cells.
Kim H; Kang JW; Lee S; Choi WJ; Jeong LS; Yang Y; Hong JT; Yoon DY
Anticancer Res; 2010 Jul; 30(7):2823-30. PubMed ID: 20683018
[TBL] [Abstract][Full Text] [Related]
40. Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor.
Ge ZD; Peart JN; Kreckler LM; Wan TC; Jacobson MA; Gross GJ; Auchampach JA
J Pharmacol Exp Ther; 2006 Dec; 319(3):1200-10. PubMed ID: 16985166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
